Ca 50

Haglund, Caj; Kuusela, Pentti; Roberts, Peter; Jalanko, Hannu

doi:10.1007/978-1-4612-0401-5_17

Serological Cancer Markers 1992

DOI: 10.1007/978-1-4612-0401-5_17

|View full text |Cite

Ca 50

Caj Haglund¹,

Pentti Kuusela²,

Peter Roberts³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1994

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA 50, defined by monoclonal antibody C 50 (C 50 antibody) (Lindholm et al, 1983), also reacts with sialylated Lewis, and in addition with at least one other carbohydrate, sialosyl-lactotetraose (Minsson et al, 1985;, although its affinity for this carbohydrate is much weaker (Minsson et al, 1985;. In spite of the broader reactivity of the C 50 antibody, the CA 19-9 assay shows a similar (Harmenberg et al, 1988) or even somewhat higher sensitivity for pancreatic cancer than the CA 50 test (Haglund et al, 1987;Benini et al, 1988).…”

mentioning

confidence: 99%

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Haglund

Lundin²,

Kuusela³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensitivity of the CA 242 assay was 74%: 55% in stage I, 83% in stage II-III and 78% in stage IV disease. The specificity calculated from 112 patients with benign diseases was 91%. CA 19-9 had a higher sensitivity of 83%, but the specificity was only 81%. When comparing the markers by receiver operating characteristic analysis, the sensitivities were almost identical at all specificity levels. The CA 242 level was elevated in 7%, 15% and 7% of patients with benign pancreatic, biliary and liver disease respectively. The corresponding figures for CA 19-9 were 19%, 28% and 15% respectively. The sensitivity of CA 242 was higher than that of CA 50 and CEA at all specificity levels. In conclusion, tumour marker CA 242 seems to be a useful diagnostic tool for the diagnosis of pancreatic cancer, and is an alternative to CA 19-9. The advantage of CA 242 over CA 19-9 is its higher specificity when using the recommended cut-off levels of the assays.

show abstract

mentioning

confidence: 99%

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Haglund

Lundin²,

Kuusela³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ca 50

Cited by 1 publication

References 26 publications

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

Contact Info

Product

Resources

About